Read by QxMD icon Read

Hematology and Oncology

Rovshan M Ismailov, Zaytuna D Khasanova
BACKGROUND: No data exist regarding oncology/hematology team members' knowledge of and views on biosimilars in Colorado, USA. Published research has suggested that health professionals may have a poor understanding of many issues related to biosimilars. OBJECTIVES: Our goal was to increase oncology/hematology team members' knowledge of biosimilars and then use an anonymous online survey to assess the knowledge gained. We also aimed to examine oncology/hematology team members' overall interest in the subject and their motivation to learn more about biosimilars in the future...
August 17, 2018: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Tae Gyu Kim, Won Park, Hakyoung Kim, Doo Ho Choi, Hee Chul Park, Seok-Hyung Kim, Yong Beom Cho, Seong Hyen Yun, Hee Cheol Kim, Woo Yong Lee, Jeeyun Lee, Ki Mun Kang
PURPOSE: There is uncertainty over the effect of systemic inflammatory response on oncologic outcomes in patients who underwent neoadjuvant chemoradiotherapy and surgery for rectal cancer. We investigated the association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) as markers of systemic inflammation and tumor response and prognosis after treatment. METHODS: A total of 176 patients who underwent neoadjuvant chemoradiotherapy and curative surgery for rectal cancer were analyzed retrospectively...
August 17, 2018: Tumori
Annarita Conconi, Emanuele Zucca, Gloria Margiotta-Casaluci, Katharine Darling, Barbara Hasse, Manuel Battegay, Cornelia Staehelin, Urban Novak, Patrick Schmid, Alexandra Scherrer, Stephan Dirnhofer, Ivo Kwee, Luca Nassi, Franco Cavalli, Gianluca Gaidano, Francesco Bertoni, Enos Bernasconi
The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = ...
August 16, 2018: Hematological Oncology
Kazushige Wakuda, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Toshiaki Takahashi
Background: The treatment efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer is unclear. Methods: We defined refractory relapse as treatment-free interval <90 days and poor-risk as Eastern Cooperative Oncology Group Performance Status ≥2. We retrospectively examined the medical record data of patients who were treated at our hospital between September 2002 and December 2014. Results: Twenty-three poor-risk patients with refractory-relapsed small-cell lung cancer were treated in our hospital...
August 3, 2018: Japanese Journal of Clinical Oncology
Xue-Fei Zhao, Hong-Yan Wang, Xu Zhao, Huan-Chen Cheng, Wei Li, Sheng-Wei Liu, Lin Qiu, Jun Ma
OBJECTIVE: To retrospectively analyze the immunophenotyping, fusion gene and gene mutation of 30 acute lymphoblastic leukemia (ALL) cases and to investigate the relationship between the analysis results and the clinical therapeutic effect and prognosis. METHODS: Thirty All phtients were collected from the First Hospital of Harbin, Institute of Hematology and Oncology Department of Pediatrics from August 2015 to June 2016. According to the classification of FAB standard, 27 cases were B system ALL, 3 cases were T system ALL...
August 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Malte Kircher, Peter Herhaus, Margret Schottelius, Andreas K Buck, Rudolf A Werner, Hans-Jürgen Wester, Ulrich Keller, Constantin Lapa
Given its prominent role in inflammation and cancer biology, the C-X-C motif chemokine receptor 4 (CXCR4) has gained a lot of attention in the recent years. This review gives a short overview of the physiology and pathology of chemokines and chemokine receptors and then focuses on the current experience of targeting CXCR4, using radiolabeled receptor ligands suitable for positron emission tomography (PET) imaging, in both hematologic and solid malignancy as well as in inflammatory conditions. Additionally, CXCR4-directed endoradiotherapy (ERT) as a new treatment option is discussed...
August 13, 2018: Annals of Nuclear Medicine
Bastien Cabarrou, Florence Dalenc, Eve Leconte, Jean-Marie Boher, Thomas Filleron
In clinical studies of hematologic and oncologic diseases, the outcomes of interest are generally composite time to event endpoints which are usually defined by occurrence of different event types. Nonetheless, clinicians are interested in studying only one event type, which leads to a competing risks situation. In this context, Pepe and Mori presented a quantity directly derived from the cumulative incidence: the conditional probability. This function defines the probability that a given event occurs, conditionally on not having had a competing event by that time...
August 4, 2018: Computers in Biology and Medicine
Suha Rizik, Fahed Hakim, Lea Bentur, Nira Arad-Cohen, Imad Kassis
BACKGROUND: Immunocompromised children are at high risk of rapid deterioration and of developing life-threatening pulmonary infections. Etiologies in this setting are diverse, including those that are infectious and noninfectious, and many etiologies may coexist. Accurate diagnosis is required for the rational use of medications. Fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) can identify infectious causes in this population. OBJECTIVES: The aims of this study were to evaluate diagnostic rate, safety, and changes in treatment following FOB with BAL, when applied with advanced laboratory diagnostic techniques...
August 10, 2018: Journal of Pediatric Hematology/oncology
Markus Ruhnke, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Axel Hamprecht, Werner Heinz, Claus-Peter Heussel, Marius Horger, Oliver Kurzai, Meinolf Karthaus, Jürgen Löffler, Georg Maschmeyer, Olaf Penack, Christina Rieger, Volker Rickerts, Jörg Ritter, Martin Schmidt-Hieber, Nikolai Schuelper, Stefan Schwartz, Andrew Ullmann, Jörg-Janne Vehreschild, Marie von Lilienfeld-Toal, Thomas Weber, Hans-H Wolf
Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life-threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other Non-Aspergillus moulds are increasingly identified in case of documented IFD. For definite diagnosis of IFD, a combination of diagnostic tools have to be applied, including conventional mycological culture and non-conventional microbiological tests such as antibody / antigen and molecular tests, as well as histopathology and radiology...
August 11, 2018: Mycoses
Douglas S Hawkins, Yueh-Yun Chi, James R Anderson, Jing Tian, Carola A S Arndt, Lisa Bomgaars, Sarah S Donaldson, Andrea Hayes-Jordan, Leo Mascarenhas, Mary Beth McCarville, Jeannine S McCune, Geoff McCowage, Lynn Million, Carol D Morris, David M Parham, David A Rodeberg, Erin R Rudzinski, Margarett Shnorhavorian, Sheri L Spunt, Stephen X Skapek, Lisa A Teot, Suzanne Wolden, Torunn I Yock, William H Meyer
Purpose Intermediate-risk rhabdomyosarcoma (RMS) includes patients with either nonmetastatic, unresected embryonal RMS (ERMS) with an unfavorable primary site or nonmetastatic alveolar RMS (ARMS). The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses. All patients received a lower dose of cyclophosphamide and earlier radiation therapy than in previous trials...
August 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Robert J Canter, William J Murphy
Immunotherapy is rapidly becoming the fourth arm of cancer treatment, and breakthrough successes have been observed in multiple malignancies. However, despite the potential for impressive anti-tumor effects, on average, only 25% of patients respond, and barriers clearly remain. Hence, uncovering innovative ways to apply immunotherapy and overcome immune resistance remains an unmet need in immuno-oncology. Natural killer (NK) cells are an attractive candidate for extending the promise of immunotherapy, although success to date has been largely limited to hematological cancers...
August 7, 2018: Journal for Immunotherapy of Cancer
Hibah Osman, Sudip Shrestha, Sarah Temin, Zipporah V Ali, Rumalie A Corvera, Henry D Ddungu, Liliana De Lima, Maria Del Pilar Estevez-Diz, Frank D Ferris, Nahla Gafer, Harmala K Gupta, Susan Horton, Graciela Jacob, Ruinuo Jia, Frank L Lu, Daniela Mosoiu, Christina Puchalski, Carole Seigel, Olaitan Soyannwo, James F Cleary
Purpose The purpose of this new resource-stratified guideline is to provide expert guidance to clinicians and policymakers on implementing palliative care of patients with cancer and their caregivers in resource-constrained settings and is intended to complement the Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update of 2016. Methods ASCO convened a multidisciplinary, multinational panel of experts in medical oncology, family medicine, radiation oncology, hematology/oncology, palliative and/or hospice care, pain and/or symptom management, patient advocacy, public health, and health economics...
July 2018: Journal of Global Oncology
Jiaxi Zhou, Jonathon Vallejo, Paul Kluetz, Richard Pazdur, Tamy Kim, Patricia Keegan, Ann Farrell, Julia A Beaver, Rajeshwari Sridhara
Background: We previously conducted an overview of oncology products reviewed by the Office of Oncology Drug Products in the Center for Drug Evaluation and Research at the US Food and Drug Administration for marketing approval and the regulatory actions taken during July 2005 to December 2007. There is a need to understand if the changes in the laws, regulations, and the organization that occurred after 2007 had any impact on the regulatory drug approvals. We present a detailed overview of hematology and oncology products reviewed by Office of Oncology Drug Products and Office of Hematology and Oncology Drug Products...
August 4, 2018: Journal of the National Cancer Institute
Sidharth Totadri, Amita Trehan, Anish Bhattacharya, Deepak Bansal, Savita Verma Attri, Radhika Srinivasan
Chylothorax is an uncommon complication in children. Although surgery and trauma are the most common causes encountered, hematological as well as solid malignancies can present with chylothorax. This study aimed to describe the presentation and management of malignant chylothorax in children. This is a case series from a pediatric hematology-oncology unit. Chylothorax was diagnosed by demonstrating high triglyceride content in the pleural fluid and a low cholesterol concentration in relation to the serum cholesterol...
October 2017: Indian Journal of Cancer
Giuseppe Lombardi, Mario Caccese, Luisa Bellu, Ardi Pambuku, Eleonora Bergo, Franco Berti, Marina P Gardiman, Alessandro Della Puppa, Luca Denaro, Sandro Dal Pos, Vittorina Zagonel
Glioblastoma is the most common and aggressive primitive brain tumor in adults. Temozolomide (TMZ) administered daily with radiation therapy, followed by adjuvant TMZ has become the standard treatment. Although TMZ treatment has been considered to have a low toxicity profile, studies have noted the development of a severe myelosuppression, especially during the concomitant treatment; this toxicity may in some cases be prolonged and consequently treatment must be definitively discontinued. We analyzed two cases treated at our oncological center who developed severe and prolonged hematological toxicity during concomitant chemoradiotherapy treatment with TMZ...
August 3, 2018: Anti-cancer Drugs
Thomas F Morris, Tracy Louise Ellison, Maysoon Mutabagani, Sahar Isa Althawadi, Martin Heppenheimer
BACKGROUND: Demand for clinical laboratory services in our insti.tution has increased by 7% each year in the past 5 years, while the amount budgeted for services has remained fixed. To address the issue, we conducted a pilot study to curb inappropriate demand by implementing a minimum retest interval (time-based restrictions on the ordering certain tests) and thus reduce costs. OBJECTIVE: Explore the impact (financial and work volume) of restricting overuse of laboratory tests that add to costs but provide no additional clinical value...
July 2018: Annals of Saudi Medicine
Junki Mizusawa, Akira Fukutomi, Hiroshi Katayama, Hiroshi Ishii, Tatsuya Ioka, Takuji Okusaka, Hideki Ueno, Makoto Ueno, Masafumi Ikeda, Nobumasa Mizuno, Masato Ozaka, Haruhiko Fukuda, Junji Furuse
Gemcitabine is one of the standard treatments for locally advanced pancreatic cancer. Recent studies on metastatic pancreatic cancer have shown that combination chemotherapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GnP) prolonged the overall survival compared with gemcitabine alone. To select the most promising chemotherapy, a randomized phase II selection design trial was started in July 2016 to compare between modified FOLFIRINOX and GnP for patients with locally advanced pancreatic cancer...
July 27, 2018: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
Samuel A Merrill, Rakhi Naik, Michael B Streiff, Satish Shanbhag, Sophie Lanzkron, Evan M Braunstein, Alison M Moliterno, Robert A Brodsky
Hemophagocytic lymphohistiocytosis (HLH) is a highly fatal, hyperinflammatory syndrome in adults triggered by an underlying illness in most cases. As such, suspicion of HLH dictates further investigation to identify the HLH trigger and determine treatment. HLH is clinically challenging due to diverse presentations and underlying triggers, provider unfamiliarity, and bleeding complications. Clinically, we observed diagnostic error from incorrect testing and cognitive biases (interleukin-2 confused with soluble interleukin-2 receptor and natural killer cell quantification confused with functional assays)...
August 2018: Medicine (Baltimore)
Tom T P Seijkens, Esther Lutgens
PURPOSE OF REVIEW: Targeted cancer therapies have revolutionized the treatment of cancer in the past decade, but cardiovascular toxicity is a rising problem in cancer patients. Here we discuss the effects of targeted cancer therapies on atherosclerosis. Increasing the awareness of these adverse effects will promote the development of evidence-based preventive strategies in the emerging field of cardiovascular oncology. RECENT FINDINGS: Vascular endothelial growth factor inhibitors, immunomodulatory imide drugs, tyrosine kinase inhibitors and immune checkpoint inhibitors are successfully used as treatment for many types of solid and hematologic malignancies...
July 31, 2018: Current Opinion in Lipidology
T Lambourne, L V Minard, H Deal, J Pitman, M Rolle, D Saulnier, J Houlihan
The medication information needs of patients with cancer have been primarily studied using quantitative methods and little qualitative research on this topic exists. The purpose of this study was to explore patients' perspectives of optimal oncology medication education provided to patients at the Nova Scotia Health Authority (NSHA). Adult (≥ 18 years) outpatients in medical, gynecological and hematology oncology at NSHA were invited to participate in focus groups, which were audio-recorded, transcribed and analyzed thematically...
August 3, 2018: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"